CYP3A5 and myopathy: However, we included those studies because in the study by Liu, atorvastatin and simvastatin comprised more than 70% of the statins administered, while in the study by Ramakumari on patients with atorvastatin and rosuvastatin in a 40:60 ratio, it was found that the CYP3A5*3 polymorphism significantly increased statin-induced myopathy.